Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41571-024-00896-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis.
Lancet Oncol
December 2024
Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy; Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS Rome, Italy. Electronic address:
Background: In advanced pancreatic ductal adenocarcinoma (PDAC), first-line chemotherapy is the standard of care. Due to the absence of head-to-head comparisons in clinical trials, we performed this systematic review and network meta-analysis to compare treatment options for PDAC in terms of their efficacy and toxicity.
Methods: PubMed, the Cochrane Central Register of Controlled Trials, Embase, and oncological meetings websites were searched until Nov 15, 2023.
NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3.
Nat Rev Clin Oncol
December 2024
David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Reply to 'NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3'.
Nat Rev Clin Oncol
December 2024
Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Consensus, debate, and prospective on pancreatic cancer treatments.
J Hematol Oncol
October 2024
Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans St, Baltimore, MD, 21287, USA.
Article Synopsis
- Pancreatic cancer is a highly aggressive disease, and despite advancements in treatment, patient prognosis has not significantly improved.
- Surgical strategies focus on achieving R0 resection in resectable cases, while the use of neoadjuvant therapy remains debated for those patients.
- Chemotherapy is the primary treatment for advanced cases, with ongoing investigations into immunotherapy and targeted therapies to enhance treatment effectiveness.
FDA endorses NALIRIFOX for metastatic pancreatic adenocarcinoma: an editorial.
Ann Med Surg (Lond)
October 2024
Faculty of Medicine, University of Khartoum, Khartoum, Sudan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!